Jubilant Pharmova Share Price
Sector: Biotechnology & Drugs
1176.95 -1.90 (-0.16%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1168.45
Today’s High
1204.30
52 Week Low
701.40
52 Week High
1309.00
1173.90 -6.10 (-0.52%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1166.20
Today’s High
1205.00
52 Week Low
701.80
52 Week High
1309.90
Key Metrics
- Market Cap (In Cr) 18760.12
- Beta 1.05
- Div. Yield (%) 0.42
- P/B 2.99
- TTM P/E 16.91
- Peg Ratio 0.84
- Sector P/E 22.67
- D/E 0
- Open Price 1193.95
- Prev Close 1178.85
Jubilant Pharmova Analysis
Price Analysis
-
1 Week4.73%
-
3 Months32.78%
-
6 Month10.3%
-
YTD6.77%
-
1 Year60.03%
Risk Meter
- 46% Low risk
- 46% Moderate risk
- 46% Balanced Risk
- 46% High risk
- 46% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 2
- 2
- 2
- 1
- Hold
- 0.00
- 0.00
- 0.00
- 0.00
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 3
- 3
- 3
- 2
Jubilant Pharmova News
Recommended stocks to buy today: Top stock picks by market experts for 21 May
7 min read . 21 May 2025Best stocks to buy today: Expert Raja Venkatraman's recommendations for 21 May
3 min read . 21 May 2025Stocks to Watch: IDFC First Bank, PNB, Dr Reddy's, REC, RIL, Welspun and more
2 min read . 30 Sep 2024Jubilant Pharmova Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 7234.5
- Selling/ General/ Admin Expenses Total
- 2267.9
- Depreciation/ Amortization
- 368.6
- Other Operating Expenses Total
- 1475.9
- Total Operating Expense
- 6069.9
- Operating Income
- 1164.6
- Net Income Before Taxes
- 980.6
- Net Income
- 839.4
- Diluted Normalized EPS
- 33.55
- Period
- 2025
- Total Assets
- 12756.4
- Total Liabilities
- 6501.5
- Total Equity
- 6254.9
- Tangible Book Valueper Share Common Eq
- 165.23
- Period
- 2025
- Cashfrom Operating Activities
- 1072.1
- Cashfrom Investing Activities
- 487.7
- Cashfrom Financing Activities
- -1452.7
- Net Changein Cash
- 131.9
- Period
- 2024
- Total Revenue
- 6702.9
- Selling/ General/ Admin Expenses Total
- 3318
- Depreciation/ Amortization
- 381.9
- Other Operating Expenses Total
- 57.8
- Total Operating Expense
- 6348.7
- Operating Income
- 354.2
- Net Income Before Taxes
- 170.5
- Net Income
- 77.1
- Diluted Normalized EPS
- 9.39
- Period
- 2024
- Total Assets
- 11548.5
- Total Liabilities
- 6114.6
- Total Equity
- 5433.9
- Tangible Book Valueper Share Common Eq
- 121.67
- Period
- 2024
- Cashfrom Operating Activities
- 971.3
- Cashfrom Investing Activities
- -607.9
- Cashfrom Financing Activities
- -432.5
- Net Changein Cash
- -57.5
- Period
- 2023
- Total Revenue
- 6281.73
- Selling/ General/ Admin Expenses Total
- 3219.05
- Depreciation/ Amortization
- 382.6
- Other Operating Expenses Total
- 56.03
- Total Operating Expense
- 6108.72
- Operating Income
- 173.01
- Net Income Before Taxes
- 27.78
- Net Income
- -60.98
- Diluted Normalized EPS
- 5.6
- Period
- 2023
- Total Assets
- 11156.65
- Total Liabilities
- 5757.37
- Total Equity
- 5399.28
- Tangible Book Valueper Share Common Eq
- 126.96
- Period
- 2023
- Cashfrom Operating Activities
- 660.67
- Cashfrom Investing Activities
- -544.41
- Cashfrom Financing Activities
- -156.68
- Net Changein Cash
- 30.1
- Period
- 2022
- Total Revenue
- 6130.16
- Selling/ General/ Admin Expenses Total
- 3107.09
- Depreciation/ Amortization
- 381.7
- Other Operating Expenses Total
- 29.93
- Total Operating Expense
- 5305.71
- Operating Income
- 824.45
- Net Income Before Taxes
- 630.45
- Net Income
- 413.94
- Diluted Normalized EPS
- 26.14
- Period
- 2022
- Total Assets
- 9990.87
- Total Liabilities
- 4672.3
- Total Equity
- 5318.56
- Tangible Book Valueper Share Common Eq
- 135.04
- Period
- 2022
- Cashfrom Operating Activities
- 837.54
- Cashfrom Investing Activities
- -380.37
- Cashfrom Financing Activities
- -32.6
- Net Changein Cash
- 481.86
- Period
- 2021
- Total Revenue
- 6098.54
- Selling/ General/ Admin Expenses Total
- 2850.19
- Depreciation/ Amortization
- 426.07
- Other Operating Expenses Total
- -75.43
- Total Operating Expense
- 5001.09
- Operating Income
- 1097.44
- Net Income Before Taxes
- 871.08
- Net Income
- 835.87
- Diluted Normalized EPS
- 38.26
- Period
- 2021
- Total Assets
- 8918.11
- Total Liabilities
- 4176.62
- Total Equity
- 4741.49
- Tangible Book Valueper Share Common Eq
- 113.77
- Period
- 2021
- Cashfrom Operating Activities
- 1707.28
- Cashfrom Investing Activities
- -739.01
- Cashfrom Financing Activities
- -1709.39
- Net Changein Cash
- -728.86
- Period
- 2020
- Total Revenue
- 5975.79
- Selling/ General/ Admin Expenses Total
- 2758.84
- Depreciation/ Amortization
- 431.55
- Other Operating Expenses Total
- -101.59
- Total Operating Expense
- 4800.38
- Operating Income
- 1175.41
- Net Income Before Taxes
- 1012.88
- Net Income
- 898.25
- Diluted Normalized EPS
- 40.43
- Period
- 2020
- Total Assets
- 12521.65
- Total Liabilities
- 6917.77
- Total Equity
- 5603.88
- Tangible Book Valueper Share Common Eq
- 174.72
- Period
- 2020
- Cashfrom Operating Activities
- 1542.94
- Cashfrom Investing Activities
- -327
- Cashfrom Financing Activities
- -1050.37
- Net Changein Cash
- 225.42
- Period
- 2019
- Total Revenue
- 9110.82
- Selling/ General/ Admin Expenses Total
- 3482.21
- Depreciation/ Amortization
- 360.3
- Other Operating Expenses Total
- 54.41
- Total Operating Expense
- 8009
- Operating Income
- 1101.82
- Net Income Before Taxes
- 903.81
- Net Income
- 574.46
- Diluted Normalized EPS
- 48.96
- Period
- 2019
- Total Assets
- 11468.51
- Total Liabilities
- 6659.59
- Total Equity
- 4808.92
- Tangible Book Valueper Share Common Eq
- 134.8
- Period
- 2019
- Cashfrom Operating Activities
- 1121.51
- Cashfrom Investing Activities
- -1011.84
- Cashfrom Financing Activities
- 657.43
- Net Changein Cash
- 761.22
- Period
- 2025-03-31
- Total Revenue
- 1928.8
- Selling/ General/ Admin Expenses Total
- 590.6
- Depreciation/ Amortization
- 95.2
- Other Operating Expenses Total
- 366.7
- Total Operating Expense
- 1681.9
- Operating Income
- 246.9
- Net Income Before Taxes
- 206
- Net Income
- 153.6
- Diluted Normalized EPS
- 9.83
- Period
- 2025-03-31
- Total Assets
- 12756.4
- Total Liabilities
- 6501.5
- Total Equity
- 6254.9
- Tangible Book Valueper Share Common Eq
- 165.23
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 1072.1
- Cashfrom Investing Activities
- 487.7
- Cashfrom Financing Activities
- -1452.7
- Net Changein Cash
- 131.9
- Period
- 2024-12-31
- Total Revenue
- 1821.7
- Selling/ General/ Admin Expenses Total
- 560.1
- Depreciation/ Amortization
- 91.3
- Other Operating Expenses Total
- 399.8
- Total Operating Expense
- 1644.5
- Operating Income
- 177.2
- Net Income Before Taxes
- 130.5
- Net Income
- 100.9
- Diluted Normalized EPS
- 7.28
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1752.3
- Selling/ General/ Admin Expenses Total
- 564.3
- Depreciation/ Amortization
- 91.4
- Other Operating Expenses Total
- 343.8
- Total Operating Expense
- 1568.5
- Operating Income
- 183.8
- Net Income Before Taxes
- 144.4
- Net Income
- 102.8
- Diluted Normalized EPS
- 7.09
- Period
- 2024-09-30
- Total Assets
- 11924.4
- Total Liabilities
- 5983.9
- Total Equity
- 5940.5
- Tangible Book Valueper Share Common Eq
- 150.71
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 327.5
- Cashfrom Investing Activities
- 635.8
- Cashfrom Financing Activities
- -848.5
- Net Changein Cash
- 120.5
- Period
- 2024-06-30
- Total Revenue
- 1731.7
- Selling/ General/ Admin Expenses Total
- 552.9
- Depreciation/ Amortization
- 90.7
- Other Operating Expenses Total
- 365.6
- Total Operating Expense
- 1175
- Operating Income
- 556.7
- Net Income Before Taxes
- 499.7
- Net Income
- 482.1
- Diluted Normalized EPS
- 6.34
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1758.6
- Selling/ General/ Admin Expenses Total
- 555
- Depreciation/ Amortization
- 101
- Other Operating Expenses Total
- 404.8
- Total Operating Expense
- 1757.1
- Operating Income
- 1.5
- Net Income Before Taxes
- -53.7
- Net Income
- -58.6
- Diluted Normalized EPS
- 3.25
- Period
- 2024-03-31
- Total Assets
- 11548.5
- Total Liabilities
- 6114.6
- Total Equity
- 5433.9
- Tangible Book Valueper Share Common Eq
- 121.67
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 971.3
- Cashfrom Investing Activities
- -607.9
- Cashfrom Financing Activities
- -432.5
- Net Changein Cash
- -57.5
- Period
- 2023-12-31
- Total Revenue
- 1677.1
- Selling/ General/ Admin Expenses Total
- 581.5
- Depreciation/ Amortization
- 94.6
- Other Operating Expenses Total
- 341.7
- Total Operating Expense
- 1553.7
- Operating Income
- 123.4
- Net Income Before Taxes
- 101
- Net Income
- 66.8
- Diluted Normalized EPS
- 4.2
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Jubilant Pharmova Technical
Moving Average
SMA
- 5 Day1132.18
- 10 Day1124.82
- 20 Day1139.45
- 50 Day1023.94
- 100 Day979.8
- 300 Day1048.97
Jubilant Pharmova Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Eris Lifesciences
- 1679.6
- 60.65
- 3.75
- 1909.55
- 988.95
- 22825.66
- Alembic Pharmaceuticals
- 974.2
- 0.15
- 0.02
- 1296.15
- 725.6
- 19149.18
- Jubilant Pharmova
- 1176.95
- -1.9
- -0.16
- 1309
- 701.4
- 18760.12
- Caplin Point Laboratories
- 2087.3
- 9.35
- 0.45
- 2636
- 1370
- 15838.86
- Natco Pharma
- 883.75
- 12.05
- 1.38
- 1638.35
- 660.05
- 15828.84
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Eris Lifesciences
- 63.07
- 7.77
- 18.25
- 20.85
- Alembic Pharmaceuticals
- 33.51
- 3.68
- 13.54
- 10.84
- Jubilant Pharmova
- 35.29
- 3
- 6.87
- 5.64
- Caplin Point Laboratories
- 30.01
- 5.62
- 21.81
- 26.11
- Natco Pharma
- 8.35
- 2.07
- 18.55
- 30.39
Jubilant Pharmova Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 16-May-25
- Audited Results & Final Dividend
- 31-Jan-25
- Quarterly Results
- 25-Oct-24
- Quarterly Results
- 19-Jul-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 02-Feb-24
- Quarterly Results
- 27-Oct-23
- Quarterly Results
- 19-Jul-23
- Quarterly Results
- 29-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Aug-24
- 12-Aug-24
- AGM
- 25-Aug-24
- 30-Jul-24
- POM
- 28-Jun-24
- 28-May-24
- POM
- 27-Jan-24
- 28-Dec-23
- POM
- 31-Aug-23
- 29-May-23
- AGM
- 23-Aug-23
- 24-Jul-23
- POM
- 14-Apr-23
- 14-Mar-23
- POM
- 26-Sept-22
- 01-Jul-22
- AGM
- 18-May-22
- 18-Apr-22
- POM
- 22-Sept-21
- 04-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 16-May-25
- 25-Jul-25
- 25-Jul-25
- 5
- 29-May-24
- 02-Aug-24
- 02-Aug-24
- 5
- 29-May-23
- 10-Aug-23
- 10-Aug-23
- 5
- 04-Jun-21
- 06-Aug-21
- 05-Aug-21
- 5


